Role of GABA Deficit in Sensitivity to the Psychotomimetic Effects of Amphetamine

Neuropsychopharmacology

Volumn 40, Issue 12, 2015, Pages 2822-2831

  Ahn, Kyung Heup ^a,b,c   Sewell, Andrew ^a,b,c   Elander, Jacqueline ^a,b,c   Pittman, Brian ^b,c   Ranganathan, Mohini ^a,b,c   Gunduz Bruce, Handan ^a,c   Krystal, John ^a,b,c   D'souza, Deepak Cyril ^a,b,c  

^a VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^b Yale University School of Medicine   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; AMPHETAMINE; BENZODIAZEPINE RECEPTOR; IOMAZENIL; FLUMAZENIL; PSYCHEDELIC AGENT;

ADULT; ARTICLE; ASSESSMENT OF HUMANS; CLINICAL ARTICLE; CLINICIAN ADMINISTERED DISSOCIATIVE SYMPTOMS SCALE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; HUMAN; LIPOPROTEIN DEFICIENCY; MALE; NEGATIVE SYNDROME; NORMAL HUMAN; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITIVE SYNDROME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VISUAL ANALOG SCALE; ADOLESCENT; ANALOGS AND DERIVATIVES; DEFICIENCY; DRUG ADMINISTRATION; MIDDLE AGED; PSYCHOLOGICAL RATING SCALE; PSYCHOTIC DISORDERS; TIME FACTOR; YOUNG ADULT;

ADOLESCENT; ADULT; AMPHETAMINE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FLUMAZENIL; GAMMA-AMINOBUTYRIC ACID; HALLUCINOGENS; HEALTHY VOLUNTEERS; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; TIME FACTORS; VISUAL ANALOG SCALE; YOUNG ADULT;

EID: 84944354789     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2015.132     Document Type: Article

References (58)

1. Abel KM, Allin MP, Hemsley DR, Geyer MA (2003). Low dose ketamine increases prepulse inhibition in healthy men. Neuropharmacology 44: 729-737.
2. Abi-Dargham A, Gil R, Krystal J, Baldwin RM, Seibyl JP, BowersMet al (1998). Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am J Psychiatry 155: 761-767.
3. Abi-Dargham A, van de Giessen E, Slifstein M, Kegeles LS, Laruelle M (2009). Baseline and amphetamine-stimulated dopamine activity are related in drug-naive schizophrenic subjects. Biol Psychiatry 65: 1091-1093.
4. Abi-Saab W, Seibyl JP, D'Souza DC, Karper LP, Gueorgueva R, Abi-Dargham A et al (2002). Ritanserin antagonism of m-chlorophenylpiperazine effects in neuroleptic-free schizophrenics patients: support for serotonin-2 receptor modulation of schizophrenia symptoms. Psychopharmacology (Berl) 162: 55-62.
5. Ahn K, Gil R, Seibyl J, Sewell RA, D'Souza DC (2011). Probing GABA receptor function in schizophrenia with iomazenil. Neuropsychopharmacology 36: 677-683.
6. Angrist BM, Gershon S (1970). The phenomenology of experimentally induced amphetamine psychosis-preliminary observations. Biol Psychiatry 2: 95-107.
7. Ball S, Busatto GF, David AS, Jones SH, Hemsley DR, Pilowsky LS et al (1998). Cognitive functioning and GABAA/benzodiazepine receptor binding in schizophrenia: a 123I-iomazenil SPET study. Biol Psychiatry 43: 107-117.
8. Bartlett EJ, Barouche F, Brodie JD, Wolkin A, Angrist B, Rotrosen J et al (1991). Stability of resting deoxyglucose metabolic values in PET studies of schizophrenia. Psychiatry Res 40: 11-20.
9. Beer HF, Blauenstein PA, Hasler PH, Delaloye B, Riccabona G, Bangerl I et al (1990). In vitro and in vivo evaluation of iodine- 123-Ro 16-0154: a new imaging agent for SPECT investigations of benzodiazepine receptors. J Nucl Med 31: 1007-1014.
10. Bell DS (1973). The experimental reproduction of amphetamine psychosis. Arch Gen Psychiatry 29: 35-40.
11. Benes FM (2000). Emerging principles of altered neural circuitry in schizophrenia. Brain Res Brain Res Rev 31: 251-269.
12. Benes FM, Berretta S (2001). GABAergic interneurons: implications for understanding schizophrenia and bipolar disorder. Neuropsychopharmacology 25: 1-27.
13. Breier A, Su TP, Saunders R, Carson RE, Kolachana BS, de Bartolomeis A et al (1997). Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci USA 94: 2569-2574.
14. Bremner JD, Krystal JH, Putnam FW, Southwick SM, Marmar C, Charney DS et al (1998). Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS). J Trauma Stress 11: 125-136.
15. Brunner E, Domhof S, Langer F (2002). Nonparametric analysis of longitudinal data in factorial experiments. John Wiley & Sons: New York, NY, pp 261.
16. Busatto GF, Pilowsky LS, Costa DC, Ell PJ, David AS, Lucey JV et al (1997). Correlation between reduced in vivo benzodiazepine receptor binding and severity of psychotic symptoms in schizophrenia. Am J Psychiatry 154: 56-63.
17. Carr DB, Sesack SR (2000). GABA-containing neurons in the rat ventral tegmental area project to the prefrontal cortex. Synapse 38: 114-123.
18. Cherlyn SY, Woon PS, Liu JJ, Ong WY, Tsai GC, Sim K (2010). Genetic association studies of glutamate, GABA and related genes in schizophrenia and bipolar disorder: a decade of advance. Neurosci Biobehav Rev 34: 958-977.
19. D'Souza DC, Abi-Saab WM, Madonick S, Forselius-Bielen K, Doersch A, Braley G et al (2005). Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol Psychiatry 57: 594-608.
20. D'Souza DC, Gil RB, Zuzarte E, MacDougall LM, Donahue L, Ebersole JS et al (2006). gamma-Aminobutyric acid-serotonin interactions in healthy men: implications for network models of psychosis and dissociation. Biol Psychiatry 59: 128-137.
21. D'Souza DC, Perry E, MacDougall L, Ammerman Y, Cooper T, Wu YT et al (2004). The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology 29: 1558-1572.
22. Goto N, Yoshimura R, Moriya J, Kakeda S, Ueda N, Ikenouchi- Sugita A et al (2009). Reduction of brain gamma-aminobutyric acid (GABA) concentrations in early-stage schizophrenia patients: 3 T Proton MRS study. Schizophr Res 112: 192-193.
23. Griffith JD, Oates JA, Cavanaugh J (1968). Paranoid episodes induced by drugs. J Am Med Assoc 205: 39.
24. Hashimoto T, Volk DW, Eggan SM, Mirnics K, Pierri JN, Sun Z et al (2003). Gene expression deficits in a subclass of GABA neurons in the prefrontal cortex of subjects with schizophrenia. J Neurosci 23: 6315-6326.
25. Hunkeler W, Mohler H, Pieri L, Polc P, Bonetti EP, Cumin R et al (1981). Selective antagonists of benzodiazepines. Nature 290: 514-516.
26. Innis RB, al-Tikriti MS, Zoghbi SS, Baldwin RM, Sybirska EH, Laruelle MA et al (1991). SPECT imaging of the benzodiazepine receptor: feasibility of in vivo potency measurements from stepwise displacement curves. J Nucl Med 32: 1754-1761.
27. Janowsky DS, el-Yousel MK, Davis JM, Sekerke HJ (1973). Provocation of schizophrenic symptoms by intravenous administration of methylphenidate. Arch Gen Psychiatry 28: 185-191.
28. Janowsky DS, Risch C (1979). Amphetamine psychosis and psychotic symptoms. Psychopharmacology (Berl) 65: 73-77.
29. Johnson EW, Woods SW, Zoghbi S, McBride BJ, Baldwin RM, Innis RB (1990). Receptor binding characterization of the benzodiazepine radioligand 125I-Ro16-0154: potential probe for SPECT brain imaging. Life Sci 47: 1535-1546.
30. Kalivas PW (1993). Neurotransmitter regulation of dopamine neurons in the ventral tegmental area. Brain Res Brain Res Rev 18: 75-113.
31. Kay SR, Opler LA, Lindenmayer JP (1989). The Positive and Negative Syndrome Scale (PANSS): rationale and standardisation. Br J Psychiatry Suppl 7: 59-67.
32. Kegeles LS, Mao X, Stanford AD, Girgis R, Ojeil N, Xu X et al (2012). Elevated prefrontal cortex gamma-aminobutyric acid and glutamate-glutamine levels in schizophrenia measured in vivo with proton magnetic resonance spectroscopy. Arch Gen Psychiatry 69: 449-459.
33. Koreen AR, Lieberman JA, Alvir J, Chakos M (1997). The behavioral effect of m-chlorophenylpiperazine (mCPP) and methylphenidate in first-episode schizophrenia and normal controls. Neuropsychopharmacology 16: 61-68.
34. Laruelle M, Abi-Dargham A, van Dyck CH, Gil R, D'Souza CD, Erdos J et al (1996). Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci USA 93: 9235-9240.
35. Lewis DA, Curley AA, Glausier JR, Volk DW (2012). Cortical parvalbumin interneurons and cognitive dysfunction in schizophrenia. Trends Neurosci 35: 57-67.
36. Lewis DA, Hashimoto T, Volk DW (2005). Cortical inhibitory neurons and schizophrenia. Nat Rev Neurosci 6: 312-324.
37. Lieberman JA, Kane JM, Alvir J (1987a). Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology (Berl) 91: 415-433.
38. Lieberman JA, Kane JM, Sarantakos S, Gadaleta D, Woerner M, Alvir J et al (1987b). Prediction of relapse in schizophrenia. Arch Gen Psychiatry 44: 597-603.
39. Murphy BL, Arnsten AF, Goldman-Rakic PS, Roth RH (1996). Increased dopamine turnover in the prefrontal cortex impairs spatial working memory performance in rats and monkeys. Proc Natl Acad Sci USA 93: 1325-1329.
40. Ohnuma T, Augood SJ, Arai H, McKenna PJ, Emson PC (1999). Measurement of GABAergic parameters in the prefrontal cortex in schizophrenia: focus on GABA content, GABA(A) receptor alpha-1 subunit messenger RNA and human GABA transporter-1 (HGAT- -1) messenger RNA expression. Neuroscience 93: 441-448.
41. Ongur D, Prescot AP, McCarthy J, Cohen BM, Renshaw PF (2010). Elevated gamma-aminobutyric acid levels in chronic schizophrenia. Biol Psychiatry 68: 667-670.
42. Rowland LM, Kontson K, West J, Edden RA, Zhu H, Wijtenburg SA et al (2013). In vivo measurements of glutamate, GABA, and NAAG in schizophrenia. Schizophr Bull 39: 1096-1104.
43. Schroder J, Bubeck B, Demisch S, Sauer H (1997). Benzodiazepine receptor distribution and diazepam binding in schizophrenia: an exploratory study. Psychiatry Res 68: 125-131.
44. Schubiger P, Hasler P (eds) (1989). Iomazenil and other Brain Receptor Tracers for SPECT. Proceedings of the 6th Bottstein Colloquim: Wurenlingen/Villigen Switzerland.
45. Sesack SR, Carr DB, Omelchenko N, Pinto A (2003). Anatomical substrates for glutamate-dopamine interactions: evidence for specificity of connections and extrasynaptic actions. Ann NY Acad Sci 1003: 36-52.
46. Tallman JF, Gallager DW (1985). The GABA-ergic system: a locus of benzodiazepine action. Annu Rev Neurosci 8: 21-44.
47. Tam SY, Roth RH (1990). Modulation of mesoprefrontal dopamine neurons by central benzodiazepine receptors. I. Pharmacological characterization. J Pharmacol Exp Ther 252: 989-996.
48. Tayoshi S, Nakataki M, Sumitani S, Taniguchi K, Shibuya-Tayoshi S, Numata S et al (2010). GABA concentration in schizophrenia patients and the effects of antipsychotic medication: a proton magnetic resonance spectroscopy study. Schizophr Res 117: 83-91.
49. Theile JW, Morikawa H, Gonzales RA, Morrisett RA (2011). GABAergic transmission modulates ethanol excitation of ventral tegmental area dopamine neurons. Neuroscience 172: 94-103.
50. Tzschentke TM (2001). Pharmacology and behavioral pharmacology of the mesocortical dopamine system. Prog Neurobiol 63: 241-320.
51. Van Bockstaele EJ, Pickel VM (1995). GABA-containing neurons in the ventral tegmental area project to the nucleus accumbens in rat brain. Brain Res 682: 215-221.
52. Verhoeff NP, Soares JC, D'Souza CD, Gil R, Degen K, Abi-Dargham A et al (1999). [123I]Iomazenil SPECT benzodiazepine receptor imaging in schizophrenia. Psychiatry Res 91: 163-173.
53. Volk DW, Austin MC, Pierri JN, Sampson AR, Lewis DA (2000). Decreased glutamic acid decarboxylase67 messenger RNA expression in a subset of prefrontal cortical gamma-aminobutyric acid neurons in subjects with schizophrenia. Arch Gen Psychiatry 57: 237-245.
54. Volk DW, Lewis DA (2002a). Impaired prefrontal inhibition in schizophrenia: relevance for cognitive dysfunction. Physiol Behav 77: 501-505.
55. Volk DW, Pierri JN, Fritschy JM, Auh S, Sampson AR, Lewis DA (2002b). Reciprocal alterations in pre- and postsynaptic inhibitory markers at chandelier cell inputs to pyramidal neurons in schizophrenia. Cereb Cortex 12: 1063-1070.
56. Westerink BH, Kwint HF, deVries JB (1996). The pharmacology of mesolimbic dopamine neurons: a dual-probe microdialysis study in the ventral tegmental area and nucleus accumbens of the rat brain. J Neurosci 16: 2605-2611.
57. Woo TU, Whitehead RE, Melchitzky DS, Lewis DA (1998). A subclass of prefrontal gamma-aminobutyric acid axon terminals are selectively altered in schizophrenia. Proc Natl Acad Sci USA 95: 5341-5346.
58. Yoon JH, Maddock RJ, Rokem A, Silver MA, Minzenberg MJ, Ragland JD et al (2010). GABA concentration is reduced in visual cortex in schizophrenia and correlates with orientation-specific surround suppression. J Neurosci 30: 3777-3781.